; Whereas country ownership and sustainability are at the core of the GAVI Alliance model, which requires GAVI-eligible countries to contribute domestic financing to a portion of their vaccine costs and directly invest in immunizing their children; Whereas 73 developing countries working with the GAVI Alliance have cofinanced new and underused vaccines supported by the GAVI Alliance, more than 18 countries will have transitioned from GAVI support by the end of 2020, and a further 10 countries (40 percent of the original set of GAVI-eligible countries) are projected to transition during GAVI’s next strategic cycle between 2021 and 2025, moving toward fully funding their immunization programs; Whereas the GAVI Alliance has transformed the market for vaccines by matching pooled demand from developing countries with secure, predictable financing to make vaccines more affordable and supply more reliable, which will result in savings of over $900,000,000 from 2021 to 2025, and encouraging research and development of new vaccines; Whereas the GAVI Alliance has played a critical role in increasing the number of global vaccine manufacturers selling to the world’s poorest countries from 5 in 2001 to 17 in 2018; Whereas the GAVI Alliance is poised to provide the most comprehensive package of support in the 2021–2025 period by financing and delivering 18 vaccines to the world’s poorest countries; Whereas the GAVI Alliance collaborates with the Global Polio Eradication Initiative on the final push to end polio, strengthening and bringing the inactivated polio vaccine into routine immunization programs; Whereas strong programs in health systems are needed to implement additional polio protection; Whereas the GAVI Alliance has made significant progress in supporting the development and stockpiling of an effective vaccine to combat Ebola; Whereas the GAVI Alliance is participating in efforts to test and implement an effective vaccine to prevent malaria, a disease that kills more than 500,000 children a year